Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionDeutsche Bank Ag\
Latest Disclosed Ownership925,919 shares
Latest Disclosed Value $ 27,509,054
Deutsche Bank Ag\ ownership in TVTX / Travere Therapeutics, Inc.

On May 6, 2026 - Deutsche Bank Ag\ filed a 13F-HR form disclosing ownership of 925,919 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $27,509,053 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 881,680 shares of Travere Therapeutics, Inc.. This represents a change in shares of 5.02% during the quarter. The current value of the position is $41,851,539 USD.

Deutsche Bank Ag\ has a history of taking positions in derivatives of the underlying security (TVTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

TVTX / Travere Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 925,919 44,239 5.02 27,509 -18.34 0.0018
2026-02-11 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 881,680 -717,615 -44.87 33,689 -11.86 0.0110
2025-11-13 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,599,295 1,082,747 209.61 38,223 400.04 0.0128
2025-08-12 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 516,548 -9,223 -1.75 7,645 -18.86 0.0028
2025-05-09 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 525,771 -6,260 -1.18 9,422 1.66 0.0037
2025-06-30 2024-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 532,031 -143,054 -21.19 9,268 -1.87 0.0036
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 532,031 -143,054 9,268 0.0036
2025-06-26 2024-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 675,085 -271,516 -28.68 9,444 21.37 0.0038
2024-11-13 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 675,085 -271,516 9,444 0.0038
2025-06-12 2024-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 946,601 -1,454,972 -60.58 7,781 -57.98 0.0035
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 946,601 -1,454,972 7,781 0.0035
2025-06-02 2024-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 2,401,573 806 0.03 18,516 -14.21 0.0086
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,401,573 806 18,516 0.0086
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,400,767 2,092,311 678.32 21,583 682.81 0.0110
2023-11-24 2023-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 308,456 -116,085 -27.34 2,758 -57.71 0.0018
2023-11-09 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 308,456 -116,085 2,758 0.0015
2023-08-14 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 424,541 -52,267 -10.96 6,521 -39.20 0.0035
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 476,808 200,381 72.49 10,723 84.47 0.0060
2023-02-13 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 276,427 -51,406 -15.68 5,813 -28.03 0.0033
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 327,833 -217,401 -39.87 8,077 -38.86 0.0049
2022-08-11 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 545,234 -28,810 -5.02 13,210 -10.71 0.0074
2022-05-13 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 574,044 176,398 44.36 14,794 19.86 0.0069
2022-02-16 2021-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 397,646 56,799 16.66 12,343 49.32 0.0055
2022-02-11 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 397,646 56,799 12,343 0.0006
2021-11-04 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 340,847 -1,082 -0.32 8,266 65.68 0.0039
2021-08-11 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 341,929 -104,640 -23.43 4,989 -55.26 0.0024
2021-05-13 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 446,569 2,288 0.51 11,151 -7.90 0.0060
2021-02-16 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 444,281 8,121 1.86 12,108 50.37 0.0074
2020-11-12 2020-09-30 13F RETROPHIN COM 761299106 436,160 4,718 1.09 8,052 -8.56 0.0055
2020-08-13 2020-06-30 13F RETROPHIN COM 761299106 431,442 13,095 3.13 8,806 44.27 0.0067
2020-05-14 2020-03-31 13F RETROPHIN COM 761299106 418,347 -1,743 -0.41 6,104 2.36 0.0054
2020-02-14 2019-12-31 13F RETROPHIN COM 761299106 420,090 -36,446 -7.98 5,963 12.72 0.0039
2019-11-14 2019-09-30 13F RETROPHIN COM 761299106 456,536 -156,256 -25.50 5,290 -57.02 0.0037
2019-08-14 2019-06-30 13F RETROPHIN COM 761299106 612,792 -166,983 -21.41 12,309 -30.23 0.0072
2019-05-15 2019-03-31 13F RETROPHIN COM 761299106 779,775 643,476 472.11 17,643 472.45 0.0105
2019-04-01 2018-12-31 13F/A-1 RETROPHIN COM 761299106 136,299 -819,818 -85.74 3,082 -88.78 0.0022
2019-02-14 2018-12-31 13F RETROPHIN COM 761299106 136,299 -51,291 3,082
2021-12-21 2018-09-30 13F/A-1 RETROPHIN COM 761299106 956,117 64,949 7.29 27,469 13.07 0.0139
2018-11-14 2018-09-30 13F RETROPHIN COM 761299106 187,590 -703,578 5,387 0.0037
2020-04-21 2018-06-30 13F/A-1 RETROPHIN COM 761299106 891,168 -156,403 -14.93 24,294 3.72 0.0121
2018-08-14 2018-06-30 13F RETROPHIN COM 761299106 392,815 -654,756 10,706 7,110.8985
2019-10-23 2018-03-31 13F/A-2 RETROPHIN COM 761299106 1,047,571 489,833 87.82 23,422 99.34 0.0112
2019-10-18 2018-03-31 13F/A-1 RETROPHIN COM 761299106 1,047,571 0 23,422 0.0112
2018-05-15 2018-03-31 13F RETROPHIN COM 761299106 775,413 217,675 17,337
2018-02-14 2017-12-31 13F RETROPHIN COM 761299106 557,738 -117,716 -17.43 11,750 -30.10 0.0075
2017-11-14 2017-09-30 13F RETROPHIN COM 761299106 675,454 -49,480 -6.83 16,809 19.59 0.0115
2017-08-11 2017-06-30 13F RETROPHIN COM 761299106 724,934 -92,428 -11.31 14,055 -6.83 0.0100
2017-05-15 2017-03-31 13F RETROPHIN COM 761299106 817,362 32,884 4.19 15,086 1.61 0.0111
2017-02-14 2016-12-31 13F RETROPHIN COM 761299106 784,478 161,149 25.85 14,847 6.44 0.0119
2016-11-14 2016-09-30 13F RETROPHIN COM 761299106 623,329 -258,748 -29.33 13,949 -11.20 0.0099
2016-08-15 2016-06-30 13F RETROPHIN COM 761299106 882,077 320,583 57.09 15,708 104.85 0.0111
2016-05-16 2016-03-31 13F RETROPHIN COM 761299106 561,494 -101,463 -15.30 7,668 -40.03 0.0058
2016-02-16 2015-12-31 13F RETROPHIN COM 761299106 662,957 -9,282 -1.38 12,786 -6.11 0.0088
2015-11-17 2015-09-30 13F RETROPHIN COM 761299106 672,239 -132,494 -16.46 13,618 -48.95 0.0105
2015-08-12 2015-06-30 13F RETROPHIN COM 761299106 804,733 126,749 18.69 26,675 64.23 0.0170
2015-05-15 2015-03-31 13F RETROPHIN COM 761299106 677,984 290,561 75.00 16,242 242.59 0.0101
2015-02-13 2014-12-31 13F RETROPHIN COM 761299106 387,423 249,472 180.84 4,741 281.42 0.0029
2014-11-14 2014-09-30 13F RETROPHIN COM 761299106 137,951 -411,138 -74.88 1,243 -80.71 0.0008
2014-08-15 2014-06-30 13F RETROPHIN COM 761299106 549,089 179,413 48.53 6,445 -17.75 0.0044
2014-05-15 2014-03-31 13F RETROPHIN COM 761299106 369,676 369,676 7,836 0.0056
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2015-05-15 2015-03-31 13F RETROPHIN COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-02-13 2014-12-31 13F RETROPHIN COM Call 450 0.00 5 25.00 n/a n/a n/a
2014-11-14 2014-09-30 13F RETROPHIN COM Call 450 4 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.